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ABSTRACT
A retrospective study of Streptococcus pneumoniae bacteraemia among adult patients in two large
teaching hospitals in Spain identified 108 (10.6%) of 1020 episodes as nosocomial pneumococcal
bloodstream infections (NPBIs). Seventy-seven clinical records with sufficient data were available for
analysis. The interval between admission and a positive blood culture was 3–135 days (median 17 days;
interquartile range 8–27). The main underlying and predisposing conditions for NPBI were malignancy
(31%), chronic obstructive pulmonary disease (28.6%), heart failure (16.9%), chronic renal failure
(15.6%), liver cirrhosis (13%) and infection with human immunodeficiency virus (13%). Overall, 31.2%
of patients developed severe sepsis, 11.7% septic shock, and 3.9% multi-organ failure. The main portals
of entry were pneumonia (70.1%), meningitis (5.2%) and primary peritonitis (5.2%). Of the responsible
serogroups, 78% were included in the 23-valent polysaccharide vaccine. Thirty-five (45.5%) patients
died, with death considered to be related to the NPBI in 21 (27.3%) cases. Following multivariate
analysis, factors that independently predicted death after adjusting for age were: ultimately fatal
underlying disease (OR, 8.9; 95% CI, 0.8–94.3; p < 0.001); rapidly fatal underlying disease (OR, 15.0; 95%
CI, 2.8–81.3; p < 0.001); heart failure (OR, 8.11; 95% CI, 1.1–60.8; p < 0.03); inadequate empirical therapy
(OR, 10.6; 95% CI, 1.2–97; p < 0.003); a severe sepsis score (OR, 9.5; 95% CI, 1.9–47.0; p < 0.001); and
septic shock or multi-organ failure (OR, 63.7; 95% CI, 4.9–820.7; p < 0.001). Adequate empirical therapy
was an independent protective factor (OR, 0.05; 95% CI, 0.04–0.58; p < 0.005), but the use of more than
one antimicrobial agent was not.
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INTRODUCTION
Nosocomial pneumococcal bloodstream infec-
tions (NPBIs) are reported infrequently in the
literature, despite the fact that they represent
8.9–41% of all pneumococcal bloodstream infec-
tions [1–8]. This study describes the incidence,
clinical manifestations, treatment and outcome
of NPBI in two large teaching hospitals in
Spain.
PATIENTS AND METHODS
Study design and settings
The study was a retrospective cohort study carried out in
two large teaching hospitals located in the city of Madrid,
Spain. The study was performed during the 8-year period
from January 1995 to December 2002, and included all adult
patients (aged > 16 years) with one or more blood cultures
from which Streptococcus pneumoniae was isolated, and who
were considered to have acquired the infection in the
hospital (see below). Charts were reviewed according to a
pre-established protocol.
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Microbiological identification and susceptibility testing
S. pneumoniae was identified using standard and well-recog-
nised procedures. Capsular serotyping of isolates was per-
formed at the Centro Nacional de Microbiologı´a (Instituto de
Salud Carlos III, Majadahonda, Madrid). Antimicrobial sus-
ceptibility tests were performed using a microdilution tech-
nique (Sensititre; Trek Diagnostic Systems, East Grinstead, UK)
and interpreted according to NCCLS recommendations [9].
Definitions and classifications
Nosocomial infections were defined according to CDC recom-
mendations [10]. NPBIs were defined as infections that were
demonstrated ‡ 72 h after admission, excluding those patients
who were suspected of having pneumococcal disease present
or in incubation at admission [11]. The underlying condition of
each patient before pneumococcal disease was rated according
to the McCabe and Jackson criteria [12], and categorised
according to the Charlson co-morbidity index [13]. The
severity of the clinical condition of each patient with NPBI
was assessed by the APACHE II score for those admitted to the
intensive care unit (ICU) [14]. The maximum severity of septic
illness until the moment of discharge or death of each patient
was assessed according to Bone’s score [15]. The following
potential predisposing conditions for nosocomial bloodstream
infections were recorded: tracheal intubation, upper or lower
gastrointestinal endoscopy, bronchoscopy, nasogastric tube
insertion, central catheter line, indwelling bladder catheter,
surgery (in the previous 7 days), use of antimicrobial agents
(within 30 days before the episode) or corticosteroids (at least
10 mg of prednisone or equivalent for at least 7 days in the
2-week period before the episode), hospitalisation within the
preceding 3 months, liver cirrhosis, diabetes mellitus, total
parenteral nutrition (before the episode), low serum albumin
(< 3 g ⁄dL), solid or haematological malignancy, heart failure,
alcoholism (> 50 g of alcohol ingestion ⁄day), splenectomy (at
any time in the past), infection with human immunodeficiency
virus, chronic obstructive pulmonary disease, and chronic
renal failure (creatine > 1.5 mg ⁄dL). The clinical origin of NPBI
was defined on the basis of clinical data or as a consequence of
the isolation of S. pneumoniae from a focus of infection.
Treatment parameters
Treatment parameters recorded were: number of active anti-
microbial agents received simultaneously for a minimum of
2 days, length of days on active antimicrobial therapy (receiv-
ing at least one active drug), and treatment with penicillins,
cephalosporins (third and fourth generation), macrolides, co-
trimoxazole, fluoroquinolones and other drugs (carbapenems,
other cephalosporins, aminoglycosides and glycopeptides).
Antimicrobial therapy during the first 24 h of treatment was
considered to be adequate when the patient received at least
one active antimicrobial agent during this period.
Outcome
Patients were finally classified as deceased or as having been
discharged. Death was classified as related to the NPBI when
persistence of a clinical picture of sepsis at death could be
attributed to pneumococcal infection, or when death occurred
during the first week after blood cultures were taken.
Statistical analysis
Quantitative variables were calculated as a mean and standard
deviation (SD). Median and interquartile range were calcula-
ted when appropriate. Categorical data were analysed using
the chi-square test or Fisher’s exact test, as appropriate, with
statistical significance set at p £ 0.05. All p values were two-
tailed. A logistic regression model was used to examine the
effects of multiple risk-factors on mortality. Variables included
in the model were those found to reach a significance level of
p < 0.1 in the univariate analysis, together with the age of the
patients, since age is known to be a variable that has an
important impact on mortality.
RESULTS
The population served by the two institutions
between 1995 and 2002 remained stable, at close
to 1 175 000 inhabitants. Between January 1995
and December 2002, there were 1092 episodes of
pneumococcal bloodstream infections in patients
of all ages, of which 1020 (93.4%) occurred in the
adult population. Overall, the estimated incidence
of pneumococcal bloodstream infections in adults
was 10.7 episodes ⁄ 100 000 inhabitants ⁄ year. Of
the 1020 episodes of pneumococcal bloodstream
infections in adults, 108 (10.6%) were considered
to be nosocomial. Clinical charts with adequate
information were available for 77 of these 108
patients.
Of the 77 patients analysed, 55 were male and 22
were female, with a mean age of 64.34 years (SD,
16.89 years). The interval between admission and
the day of positive blood cultures for S. pneumoniae
ranged from 3 to 135 days (median, 17 days;
interquartile range, 8–27 days). Patients with NPBI
were located mainly in medical units (76.6%),
followed by surgical departments (13%) and ICUs
(10.4%). There was no evidence of nosocomial
outbreaks or in-hospital transmission. The main
underlying and predisposing conditions of the
patients with NPBI are summarised in Table 1.
The severity of the underlying condition was:
rapidly fatal, 8 (10.4%); ultimately fatal, 34
(44.2%); and non-fatal, 35 (45.5%). Co-morbidity
was variable and ranged from 0 to 11 (median 2;
interquartile range 2–7), according to Charlson’s
index. The mean APACHE II score of the 17
patients who were admitted to the ICU ranged
from 6 to 25 (mean, 13.18; SD, 6.19). The percent-
ages of patients who developed different degrees
of sepsis were: sepsis only, 53.2%; severe sepsis,
31.2%; septic shock, 11.7%; and multi-organ
failure, 3.9%.
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Portals of entry of NPBI were pneumonia
(70.1%), meningitis (5.2%), primary peritonitis
(5.2%), catheter infection (3.9%), upper respirat-
ory tract infection (2.6%) and bone and joint
infection (1.3%). NPBI presented as primary
bacteraemia in 11.7% of the episodes. The episode
was monomicrobial in 66 (85.7%) patients, and
part of a polymicrobial bacteraemia in 11 (14.3%)
patients. In polymicrobial cases, the accompany-
ing microorganisms were Staphylococcus aureus
(seven patients), Corynebacterium spp. (two
patients), Bacteroides fragilis, Pseudomonas aerugi-
nosa, Salmonella enteritidis and Haemophilus influen-
zae (one patient each).
In total, 57 (74.0%) patients had chest X-ray
abnormalities. More than one lobe of the lung
parenchyma was involved in 25 (32.5%) patients.
There were cavitations in three patients, and a
lung abscess in one case. Overall, 23 (29.9%)
patients had pleural effusions of different sizes.
Serotyping results were available for the
isolates from 72 patients (Table 2). The most
common serotypes were 14 (16.7%), 23F (11.1%)
and 19 (6.9%). Overall, 78.0% of the serogroups
obtained in this series are included in the
23-valent polysaccharide vaccine.
Antimicrobial susceptibilities were available for
all the bloodstream isolates; the frequencies of
penicillin-susceptible, -intermediate and -resistant
isolates were 54.5%, 18.2% and 27.3%, respect-
ively. With respect to other drugs, the frequency
of resistant isolates was as follows: cefotaxime,
9.2%; erythromycin, 24.7%; tetracycline, 35.1%;
chloramphenicol, 23.7%; clindamycin, 22.1%; and
trimethoprim–sulphamethoxazole, 38.7%.
Treatment and outcome
The numbers of patients who received different
antimicrobial agents were: third- or fourth-
generation cephalosporins, 41 (53.2%); penicillins,
31 (40.2%); fluoroquinolones, 11 (14.3%); macro-
lides, 6 (7.8%); trimethoprim–sulphamethoxazole,
1 (1.3%); and other antimicrobial agents, 41
(52.2%). Two or more effective drugs were
administered simultaneously to 20 (26%) patients
for at least 48 h. The mean duration of treatment
was 11.75 days (SD 6.99; range 0–31 days). Empir-
ical therapy was considered adequate for 65
(84.4%) patients.
Overall, 35 (45.5%) patients died with NPBI;
death was considered to be related directly to the
NPBI in 21 (27.3%) patients, and was considered
to be unrelated in the remaining 14 (18.2%).
Patients who received more than one active drug
had a mortality rate of 35% (7 ⁄ 20), compared with
49% (28 ⁄ 57) for those who received a single active
drug (p 0.27). Factors that correlated with mor-
tality (p < 0.10) in a univariate analysis were:
Table 1. Main underlying conditions and predisposing
factors for 77 patients with nosocomial pneumococcal
bloodstream infections in two hospitals in Spain (1995–
2002)
% of patients
Underlying condition
Malignancy 31
Chronic obstructive pulmonary disease 28.6
Heart failure 16.9
Chronic renal failure 15.6
Liver cirrhosis 13
HIV infection 13
Diabetes mellitus 11.7
Alcoholism 10.4
Splenectomy 0
Predisposing factor
Low serum albumin 54.5
Antimicrobial agents 45.5
Corticosteroids 44.2
Bladder catheter 32.5
Prior hospitalisation 23.4
Central catheter 23.4
Nasogastric tube 18.2
Tracheal intubation 18.2
Prior surgery 10.4
Gastroenteric endoscopy 9.1
Bronchoscopy 9.1
Parenteral nutrition 7.8
HIV, human immunodeficiency virus.
Table 2. Serotypes of 72 Streptococcus pneumoniae isolates
from patients with nosocomial pneumococcal bloodstream
infections in two hospitals in Spain (1995–2002)
Serotypes n %
14 12 16.7
23F 8 11.1
19 5 6.9
4 4 5.6
10 4 5.6
15F 4 5.6
8 3 4.2
23 3 4.2
34 3 4.2
3 2 2.8
6A 2 2.8
9N 2 2.8
9V 2 2.8
15 2 2.8
19F 2 2.8
23A 2 2.8
6 1 1.4
6B 1 1.4
11 1 1.4
15A 1 1.4
15B 1 1.4
18C 1 1.4
22 1 1.4
25 1 1.4
42 1 1.4
Non-typeable 3 4.2
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a rapidly or ultimately fatal disease on the
McCabe scale (p 0.006); a severe sepsis score
(p < 0.001); inadequate empirical antimicrobial
therapy during the first 24 h (p 0.009); heart
failure (p 0.016); and polymicrobial bacteraemia
(p 0.008) (Table 3).
Following multivariate analysis, factors that
independently predicted death after adjusting by
age were: ultimately fatal underlying disease (OR,
8.9; 95% CI, 0.8–94.3; p < 0.001); rapidly fatal
underlying disease (OR, 15.0; 95% CI, 2.8–81.3;
p < 0.001); heart failure (OR, 8.11; 95% CI, 1.1–
60.8; p 0.03); inadequate empirical therapy (OR,
10.6; 95% CI, 1.2–97; p < 0.003); and a severe
sepsis score (severe sepsis: OR, 9.5; 95% CI, 1.9–
47.0; p < 0.001; septic shock or multi-organ fail-
ure: OR, 63.7; 95% CI, 4.9–820.7; p < 0.001).
Adequate empirical therapy was found to be an
independent protective factor (OR, 0.05; 95% CI,
0.04–0.58; p < 0.005). The predictive ability of the
variables included in the model was 80% sensi-
tivity to predict death and 93% specificity to
predict survival.
DISCUSSION
This study shows that a significant proportion of
bactaeremic pneumococcal infections appear in
the hospital setting. NPBI usually appears in
patients with severe underlying diseases and is
associated with a high mortality. Pneumococcal
infections in children and adults are mainly
community-acquired; however, S. pneumoniae
was already recognised as a common cause of
nosocomial infection before the introduction of
penicillin into clinical practice [16,17]. In the
antibiotic era, nosocomial pneumococcal infec-
tions have been reported to account for 4% of
cases of acute sinusitis, 5% of cases of bacterial
meningitis and 2% of bacteraemias [18–22]. In a
prospective study of all infections caused by
S. pneumonia in one of the institutions in Madrid
during a 22-month period, pneumococcal infec-
tion was nosocomial in 25% of cases [23]. Some
subgroups of patients, such as the elderly, those
with malignancy, and those with ultimately fatal
diseases, have a much higher rate of nosocomial
pneumococcal infection [24–27]. The incidence of
pneumococcal bloodstream infections in Madrid
increased significantly between 1986 and 2000, in
both adults (from 8.2 to 16 episodes ⁄ 100 000
population) and children (from 3.6 to 14.8
episodes ⁄ 100 000 population) [28]. Similar increa-
ses have been demonstrated in other geographical
areas [29–33].
The proportion of pneumococcal bloodstream
infections occurring in hospitalised patients is
estimated to represent 10–41% of all cases [4,8,34].
It can be argued that many of the so-called NPBIs
are actually community-acquired, but manifest
Table 3. Comparison of patients who died and survived
(univariate analysis)
Survived
(n = 42)
Died
(n = 35) p
Age (years) 61.5 ± 17.3 67.7 ± 15.9 0.1
Male 31 (73.8%) 24 (68.6%) 0.6
Hospital 1 10 (23.8%) 12 (34.3%) 0.3
Hospital 2 32 (76.2%) 23 (65.7%) 0.3
Medical service 34 (81.0%) 25 (71.4%) 0.2
Surgical service 6 (14.3%) 4 (11.4%) 0.2
Intensive care unit 2 (4.8%) 6 (17.1%) 0.2
Classification of underlying diseasea
McCabe I 3 (7.1%) 5 (14.3%) 0.006
McCabe II 13 (31.0%) 21 (60.0%) 0.006
McCabe III 26 (61.9%) 9 (25.7%) 0.006
Underlying diseases
Liver cirrhosis 5 (11.9%) 5 (14.3%) 0.7
Diabetes 4 (9.5%) 5 (14.3%) 0.5
Malignancy 13 (31.0%) 11 (31.4%) 0.9
Heart failurea 3 (7.1%) 10 (28.6%) 0.016
Alcoholism 5 (11.9%) 3 (8.6%) 0.6
HIV infection 7 (16.7%) 3 (8.6%) 0.3
Chronic obstructive pulmonary disease 12 (28.6%) 10 (28.6%) 1.0
Chronic renal failure 5 (11.9%) 7 (20.0%) 0.3
Sepsis scorea
Sepsis 31 (73.8%) 10 (28.6%) < 0.001
Severe sepsis 10 (23.8%) 14 (40.0%) < 0.001
Septic shock 1 (2.4%) 8 (22.9%) < 0.001
Multi-organ failure 0 (0%) 3 (8.6%) < 0.001
Predisposing conditions
Mechanical ventilation 8 (19.0%) 6 (17.1%) 0.8
Gastrointestinal endoscopy 4 (9.5%) 3 (8.6%) 0.8
Bronchoscopy 4 (9.5%) 3 (8.6%) 0.8
Nasogastric tube 6 (14.3%) 8 (22.9%) 0.3
Prior antibiotic therapy 20 (47.6%) 15 (42.9%) 0.6
Prior hospital admission 10 (23.8%) 8 (22.9%) 0.9
Corticosteroid therapy 18 (42.9%) 16 (45.7%) 0.8
Prior surgery 4 (9.5%) 4 (11.4%) 0.7
Parenteral nutrition 3 (7.1%) 3 (8.6%) 0.8
Low serum albumin 22 (52.4%) 20 (57.1%) 0.6
Central catheter line 11 (26.2%) 7 (20.0%) 0.5
Indwelling bladder catheter 12 (28.6%) 13 (37.1%) 0.4
Origin of pneumococcal infection
Pneumonia 27 (64.3%) 27 (77.1%) 0.3
Upper respiratory tract 2 (4.8%) 0 (0%) 0.3
Central catheter 3 (7.1%) 0 (0%) 0.3
Primary peritonitis 2 (4.8%) 2 (5.7%) 0.3
Bone and joint infection 0 (0%) 1 (2.9%) 0.3
Meningitis 2 (4.8%) 2 (5.7%) 0.3
Primary infection 6 (14.3%) 3 (8.6%) 0.3
Chest X-ray abnormalities
Pleural effusions 11 (26.2%) 12 (34.3%) 0.4
Cavitations 1 (2.4%) 2 (5.7%) 0.4
Lung abscess 1 (2.4%) 0 (0%) 0.3
Abnormalities present 30 (71.4%) 28 (80.0%) 0.6
More than one lobe involved 12 (28.6%) 13 (37.1%) 0.4
Polymicrobial bacteraemiaa 9 (21.4%) 2 (5.7%) 0.008
Antimicrobial susceptibility
Penicillin-susceptible 23 (54.8%) 19 (54.3%) 0.9
Cefotaxime-susceptible 38 (90.5%) 32 (91.4%) 0.8
Erythromycin-susceptible 31 (73.8%) 27 (77.1%) 0.7
Therapy
Adequate therapya 40 (95.2%) 25 (71.4%) 0.004
More than two effective drugs 13 (31.0%) 7 (20.0%) 0.2
HIV, human immunodeficiency virus.
ap £ 0.05.
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following hospital admission with a delay slightly
over the breakpoint of 48 h. The present study
only included episodes that manifested ‡ 72 h
following hospitalisation of patients with no
evidence of infection on admission. The study
confirmed that NPBI tends to occur after a
relatively prolonged period of hospitalisation
(mean period of 22.56 days), a result that is quite
similar to the mean of 17 days reported by Canet
et al. [8] from another hospital in Spain. There was
no evidence, either epidemiological or based on
the identification of serotypes, for any major or
minor outbreak that might result in nosocomial
transmission from patient to patient in the insti-
tutions studied.
NPBI occurred mainly in patients with severe
underlying conditions, including neoplasia, chro-
nic obstructive pulmonary disease, heart failure,
renal failure and cirrhosis [4,26,35]. Almost half of
the patients in the present series developed severe
forms of sepsis, including septic shock or multi-
organ failure, and a high proportion required ICU
admission [4]. The series found that lung infec-
tions were the portal of entry in only 70% of
cases, and that the absence of pneumonia does not
rule out the possible presence of S. pneumoniae in
the blood cultures of hospitalised patients. NPBI
may also occur as a complication of a wide variety
of focal infections, including peritonitis, menin-
gitis, and catheter, upper respiratory tract and
bone and joint infections. In addition, NPBI can
appear as ‘primary’ bactaeremia in a significant
proportion of patients [8].
NPBI is associated with a higher mortality rate
(40–74%) [3,8,36] than community-acquired infec-
tion (14–27%) [37,38]. The above-mentioned con-
ditions explain the high mortality in the series,
which was independently predictable on the basis
of the severity of sepsis, presence of heart failure
and administration of inadequate antimicrobial
therapy. The most obvious area for potential
intervention is inadequate antimicrobial therapy.
The question of treatment with single vs. double
antimicrobial agents for severe pneumococcal
infections has been discussed previously [39–42].
The present study found that there was a trend
towards a better prognosis for those patients who
received two active antimicrobial agents, but this
did not reach statistical significance, probably
because of the limited number of patients.
The worldwide escalation of antimicrobial
resistance in S. pneumoniae has prompted the
introduction of vaccination [4], and > 70% of the
isolates responsible for nosocomial infections in
the present study would have been covered by
the 23-valent polysaccharide vaccine. Unfortu-
nately, pneumococcal vaccination was not a
common practice in Spain during the period of
the study. It is clear that S. pneumoniae infections
should be added to the list of severe nosocomial
diseases. NPBI has a severe prognosis that
justifies novel therapeutic and prevention
strategies.
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